Vida Ventures — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+7 more
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)Lewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)David Southwell(Executive Officer, Director)
BoardRobert Mittendorff(Director)
Board seatStefan Vitorovic· per SEC Form D
Co-investorsDroia VenturesARCH Venture PartnersB Capital GroupB4 Capital
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)Ying Huang(Director)Derek Metzger(Executive Officer)
BoardMaha Katabi(Director)Perry Nisen(Executive Officer, Director)Maria Fardis(Director)
Co-investorsLongitude CapitalSofinnova VenturesBiotechnology Value FundFrazier Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.